NCT02323867Completed
Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies
Unrelated and Partially Matched Related Donor Peripheral Stem Cell Transplantation With Alpha/Beta T-Cell and B-Cell Depletion for Patients With Hematologic Malignancies
Source: ClinicalTrials.gov · Last updated 6 Oct 2026
Brief summary (registry, in English)
This is a single-arm study evaluating allogeneic hematopoietic stem cell transplantation (HSCT) using mobilized peripheral blood stem cells from unrelated or partially matched related donors that are ex vivo depleted of α/β T cells and CD19+ B cells using the CliniMACS device. The study assesses engraftment, graft-versus-host disease (GVHD), treatment-related mortality, immune reconstitution, and one-year leukemia-free survival in patients with hematologic malignancies.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 98 (actual)
- First submitted
- 22 Oct 2014
- Start date
- Oct 2014
- Primary completion date
- Jul 2025
- Lead sponsor
- Children's Hospital of Philadelphia
- NCT number
- NCT02323867
What you commit to
- Study type: Interventional
- Participants enrolled: 98
- From Oct 2014 to the primary completion date, Jul 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior allogeneic stem cell transplantation
Other illness
- Does not meet disease eligibility criteria
- Inadequate organ function or uncontrolled infection
Other
- No suitable donor available
Who the study is looking for
- Age 23 or less years at time of enrollment
- Diagnosis of a hematologic malignancy, including:
- Acute myeloid leukemia (primary or secondary) in remission or \<10% bone marrow blasts
- Acute lymphoblastic leukemia in hematologic remission
- Myelodysplastic syndrome
- Chronic myelogenous leukemia (chronic phase, accelerated phase, or blast crisis in second chronic phase)
- Mixed lineage or biphenotypic acute leukemia
- Lymphoblastic lymphoma in remission
- Burkitt lymphoma/leukemia in remission
- Eligible for allogeneic hematopoietic stem cell transplantation (HSCT) per institutional criteria:
- Availability of an appropriate donor:
- Unrelated donor with up to one antigen mismatch or defined allele mismatch
- Partially matched related donor, including haploidentical donors
- Adequate organ function as per institutional bone marrow transplant (BMT) standards
- No active, uncontrolled infection
- Patients with prior fungal infection must have received ≥2 weeks of appropriate therapy and be clinically stable
- Negative pregnancy test for females of childbearing potential
- Ability to provide informed consent (≥18 years) or consent provided by parent/legal guardian
Age in the registry: - to 23 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Children's Hospital Of Philadelphia Coordinator of this site? Confirm its status | Philadelphia | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.